Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

REGENERON PHARMACEUTICALS INC

Form 4

Common

Stock

November 09, 2012

FORM	П Д								OMB AP	PROVAL	
	UNITED	STATES		RITIES A shington			NGE CO	OMMISSION	OMB Number:	3235-0287	
Check the if no lon	ger								Expires:	January 31, 2005	
subject to Section 1 Form 4 c	51A1EN 16.	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES								verage s per 0.5	
may con	Section 17(a) of the Public Utility Holding Company Act of 1935 or Sec ay continue. 30(h) of the Investment Company Act of 1940										
(Print or Type	Responses)										
1. Name and Address of Reporting Person ** Powchik Peter			Symbol					5. Relationship of Reporting Person(s) to Issuer			
		REGENERON PHARMACEUTICALS INC [REGN]					(Check all applicable) Director 10% Owner				
(Last)	(Last) (First) (Middle) 3. Date (Mont				ransaction			_X_ Officer (give title Other (specify below) SVP Clinical Development & Reg			
777 OLD S ROAD	AW MILL RIVE	R	11/08/2	-				SVP Clinical	Development	& Reg	
	(Street)			endment, Danienth/Day/Yea	_	l	I	5. Individual or Joi Applicable Line) _X_ Form filed by O			
TARRYTO	WN, NY 10591						-	Form filed by Mo			
(City)	(State)	(Zip)	Tab	le I - Non-I	Derivative	Secur	ities Acqui	ired, Disposed of,	or Beneficiall	y Owned	
(Instr. 3) any		Execution	Date, if Transaction Dispose Code (Instr. 3, 4					Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V	Amount	(D)	Price \$	(Instr. 3 and 4)			
Common Stock	11/08/2012			S	14,244	D	138.59	15,890	D		
Common Stock	11/08/2012			S	900	D	\$ 139.05 (2)	14,990	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

By 401(k)

Plan

1,532

I

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exerc	cisable and	7. Titl	le and	8. Price of	9. Nu
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	onNumber	Expiration Date		Amou	ınt of	Derivative	Deriv
Security	or Exercise		any	Code	of	(Month/Day/	Year)	Under	lying	Security	Secui
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative	e		Secur	ities	(Instr. 5)	Bene
	Derivative				Securities			(Instr.	3 and 4)		Own
	Security				Acquired						Follo
					(A) or						Repo
					Disposed						Trans
					of (D)						(Instr
					(Instr. 3,						
					4, and 5)						
									Amount		
						Date	Expiration	Title	or Number		
						Exercisable Date		of			
				Code V	(A) (D)				Shares		
				Coue v	(A) (D)				Shares		

Reporting Owners

Relationships Reporting Owner Name / Address

> Director 10% Owner Officer Other

Powchik Peter 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591

SVP Clinical Development &

Reg

Signatures

/s/**Peter 11/09/2012 Powchik

**Signature of Date Reporting Person

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Represents volume-weighted average price of sales of 14,244 shares of Company stock on November 8, 2012 at prices ranging from (1) \$138.47 to \$138.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 8, 2012 at each separate price.
- Represents volume-weighted average price of sales of 900 shares of Company stock on November 8, 2012 at prices ranging from \$139.00 (2) to \$139.27. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 8, 2012 at each separate price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2